Blueprint Medicines (BPMC) reported a Q4 net loss Thursday of $0.79 per diluted share, narrowing from a loss of $1.82 a year earlier.
Analysts polled by FactSet expected a loss of $0.67.
Revenue for the quarter ended Dec. 31, 2024, was $146.4 million, up from $72 million a year earlier.
Analysts surveyed by FactSet expected $146 million.
The company's shares were down nearly 9% in recent Thursday premarket activity.
Price: 94.50, Change: -9.06, Percent Change: -8.8
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。